CN111417632A - 噻唑-5-甲酸衍生物及其制备方法与应用 - Google Patents

噻唑-5-甲酸衍生物及其制备方法与应用 Download PDF

Info

Publication number
CN111417632A
CN111417632A CN201980005928.XA CN201980005928A CN111417632A CN 111417632 A CN111417632 A CN 111417632A CN 201980005928 A CN201980005928 A CN 201980005928A CN 111417632 A CN111417632 A CN 111417632A
Authority
CN
China
Prior art keywords
group
alkyl
thiazole
acid derivative
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980005928.XA
Other languages
English (en)
Other versions
CN111417632B (zh
Inventor
王海勇
孙明杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BEIJING XINTIANYU TECHNOLOGY DEVELOPMENT CO LTD
Original Assignee
BEIJING XINTIANYU TECHNOLOGY DEVELOPMENT CO LTD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BEIJING XINTIANYU TECHNOLOGY DEVELOPMENT CO LTD filed Critical BEIJING XINTIANYU TECHNOLOGY DEVELOPMENT CO LTD
Publication of CN111417632A publication Critical patent/CN111417632A/zh
Application granted granted Critical
Publication of CN111417632B publication Critical patent/CN111417632B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/10—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明涉及一种噻唑‑5‑甲酸衍生物，其立体异构体和可药用的盐，所述噻唑‑5‑甲酸衍生物的结构如通式(I)所示。本发明所述通式(I)化合物、其立体异构体和/或其可药用的盐可以用于制备预防或治疗高尿酸血症和/或痛风的药物，且可制备成各种给药途径的剂型。本发明提供的化合物具有良好的耐受性、安全性和优异的降尿酸活性。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201980005928.XA 2018-01-23 2019-01-18 噻唑-5-甲酸衍生物及其制备方法与应用 Active CN111417632B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018100640468 2018-01-23
CN201810064046.8A CN110066258A (zh) 2018-01-23 2018-01-23 噻唑-5-甲酸衍生物及其制备方法与应用
PCT/CN2019/072273 WO2019144842A1 (zh) 2018-01-23 2019-01-18 噻唑-5-甲酸衍生物及其制备方法与应用

Publications (2)

Publication Number Publication Date
CN111417632A true CN111417632A (zh) 2020-07-14
CN111417632B CN111417632B (zh) 2023-05-16

Family

ID=67365057

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810064046.8A Pending CN110066258A (zh) 2018-01-23 2018-01-23 噻唑-5-甲酸衍生物及其制备方法与应用
CN201980005928.XA Active CN111417632B (zh) 2018-01-23 2019-01-18 噻唑-5-甲酸衍生物及其制备方法与应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201810064046.8A Pending CN110066258A (zh) 2018-01-23 2018-01-23 噻唑-5-甲酸衍生物及其制备方法与应用

Country Status (5)

Country Link
US (1) US11401247B2 (zh)
EP (1) EP3744720A4 (zh)
JP (1) JP7154471B2 (zh)
CN (2) CN110066258A (zh)
WO (1) WO2019144842A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210130016A (ko) * 2020-04-21 2021-10-29 (주)헥사파마텍 신규의 2-아릴티아졸 유도체 또는 이의 염, 이의 제조방법, 및 이를 함유하는 약학 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011073617A1 (en) * 2009-12-14 2011-06-23 Cipla Limited Processes for the preparation of febuxostat and salts thereof
CN102333765A (zh) * 2009-02-27 2012-01-25 帝人制药株式会社 基于使用过渡金属催化剂的偶联法的苯基取代杂环衍生物的制造方法
CN105218479A (zh) * 2014-06-23 2016-01-06 北京新天宇科技开发有限公司 2-[3-氰基-4-异丁氧基苯基]-4-甲基噻唑-5-甲酸的新型衍生物、其制备方法和应用
CN106470981A (zh) * 2014-06-23 2017-03-01 北京新天宇科技开发有限公司 2‑[3‑氰基‑4‑异丁氧基苯基]‑4‑甲基噻唑‑5‑甲酸的新型衍生物、其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2073981C (en) * 1990-11-30 2002-01-08 Shiro Kondo 2-arylthiazole derivatives and pharmaceutical composition thereof
JP5291791B2 (ja) 2009-03-04 2013-09-18 株式会社島津製作所 ［１８ｆ］ｓｆｂの合成方法
CN102643249A (zh) * 2011-02-18 2012-08-22 苏州波锐生物医药科技有限公司 2-芳基噻唑衍生物,其可药用盐及用途
CN103880775B (zh) * 2012-12-21 2016-02-10 安徽省庆云医药化工有限公司 化合物2-（3-醛基-4-异丁氧基苯基）-4-甲基噻唑-5-甲酸乙酯及非布索坦的制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102333765A (zh) * 2009-02-27 2012-01-25 帝人制药株式会社 基于使用过渡金属催化剂的偶联法的苯基取代杂环衍生物的制造方法
WO2011073617A1 (en) * 2009-12-14 2011-06-23 Cipla Limited Processes for the preparation of febuxostat and salts thereof
CN105218479A (zh) * 2014-06-23 2016-01-06 北京新天宇科技开发有限公司 2-[3-氰基-4-异丁氧基苯基]-4-甲基噻唑-5-甲酸的新型衍生物、其制备方法和应用
CN106470981A (zh) * 2014-06-23 2017-03-01 北京新天宇科技开发有限公司 2‑[3‑氰基‑4‑异丁氧基苯基]‑4‑甲基噻唑‑5‑甲酸的新型衍生物、其制备方法和应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KURUVA CHANDRA SEKHAR ET AL.: "Augmenting the Xanthine Oxidase Inhibitory Activity of Febuxostat by its Structural Modification", 《LETTERS IN DRUG DESIGN & DISCOVERY》 *
M. MUKOYOSHI ET AL.: "In vitro drug–drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition", 《XENOBIOTICA》 *
RAVENDRA BABU KILARU ET AL.: "Design, synthesis, in silico and in vitro studies of novel 4-methylthiazole-5-carboxylic acid derivatives as potent anti-cancer agents", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
TILL HAUENSCHILD ET AL.: "Characterizing Active Pharmaceutical Ingredient Binding to Human Serum Albumin by Spin-Labeling and EPR Spectroscopy", 《CHEM. EUR. J.》 *

Also Published As

Publication number Publication date
JP2021510377A (ja) 2021-04-22
CN111417632B (zh) 2023-05-16
US20210024474A1 (en) 2021-01-28
CN110066258A (zh) 2019-07-30
EP3744720A1 (en) 2020-12-02
US11401247B2 (en) 2022-08-02
JP7154471B2 (ja) 2022-10-18
WO2019144842A1 (zh) 2019-08-01
EP3744720A4 (en) 2021-11-24

Similar Documents

Publication Publication Date Title
PT88261B (pt) Processo para a preparacao de nucleosidos com efeito terapeutico
EA023804B1 (ru) Оксабициклогептаны, их получение и применение
WO2015188609A1 (zh) 苯并吡喃衍生物在制备治疗高尿酸血症药物中的新用途
CN111417632B (zh) 噻唑-5-甲酸衍生物及其制备方法与应用
CN105218479B (zh) 2-[3-氰基-4-异丁氧基苯基]-4-甲基噻唑-5-甲酸的新型衍生物、其制备方法和应用
CN108997315B (zh) N-（3-氮唑基苯基）异烟酰胺类化合物及其制备方法和用途
CN109180679B (zh) 一类N-取代吡唑并[3,4-d]嘧啶酮类化合物及其制备方法和应用
JPS61210071A (ja) 抗高血圧性ジヒドロピリジン誘導体
EP0686631B1 (en) Pyrimidine derivatives and pharmaceutical compositions
CN111320662B (zh) 一类n-苄基取代的二脒那秦衍生物及其药物用途
US5621003A (en) Maillard reaction inhibitor
CN110078668B (zh) 一种苯基咪唑类xor抑制剂及制备与应用
CN111187222B (zh) 一种取代嘧啶类衍生物及其制备方法和应用
CN105272984B (zh) 吡唑并[3,4-d]嘧啶-4-酮衍生物、其制备方法和应用
CN115925640A (zh) ((3-氨甲酰-5-氟吡嗪-2-基)氧基)甲基异丁酸酯及其制备方法和应用
CN115073447A (zh) 小檗碱型吡啶甲酸类季铵盐化合物及其制备药物的用途
WO2000004001A1 (fr) Piperazinones substituees et leurs applications en therapeutique
CN112574160B (zh) 一种高良姜素衍生物及其制备方法和应用
EP1098888A1 (fr) Derives de piperazinones et leurs applications
CN110092799B (zh) 一种环状化合物、其制备方法和应用
CN104418822A (zh) 具有黄嘌呤氧化酶抑制活性的化合物及其用途
CN109503695B (zh) 熊果酸锂及其合成方法与在预防和治疗阿尔茨海默病中的应用
US20230322738A1 (en) Prodrug of pyrrolidone derivatives as glucokinase activator
US20220127273A1 (en) Salt of aldose reductase inhibitor, and preparation method and application thereof
JPS59225187A (ja) テトラヒドロ−β−カルボリン誘導体及びその製法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Wang Haiyong

Inventor after: Sun Mingjie

Inventor after: Zhang Zeheng

Inventor before: Wang Haiyong

Inventor before: Sun Mingjie

GR01 Patent grant
GR01 Patent grant